Thursday, March 14
Friday, March 15

Thursday, March 14

7:30am - 8:30am: Breakfast & Poster Presentations

8:30am - 9:30am: Concurrent Sessions I

Science Track: Personalized Medicine & Companion Diagnostics

Panelists:

• Kevin Krenitsky, MD, Chief Commercial Officer and Senior Vice President, International Strategy, Foundation Medicine
• Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics and Professor of Medicine, Harvard Medical School
• Jeffrey Luber, JD, Vice President and Co-Founder, SynapDx

Moderator:

• Jeffrey Elton, PhD, Managing Director, Life Sciences, Accenture

Business Track: What Does Pharma Really Want? External R&D

Panelists:

• Detlev Biniszkiewicz, PhD, Vice President, Oncology Innovative Medicines Unit, AstraZeneca
• Torben Straight Nissen, PhD, Managing Director, Centers for Therapeutics Innovation, Pfizer                    
• Sridaran Natesan, PhD, Vice President for External Innovation, Sanofi             

Moderator:

• Christopher Leo, PhD, Senior Vice President, Back Bay Life Science Advisors                     

9:30-9:45am: Coffee Break

9:45am-10:15am: Welcome Remarks & Overview of Meeting

• Robert K. Coughlin, President & CEO, MassBio
• Alan Moses, MD, Senior Vice President and Global Chief Medical Officer, Novo Nordisk

10:15-11:15: Keynote I: John Crowley, Chairman & CEO, Amicus Therapeutics

The major motion picture, Extraordinary Measures, starring Brendan Fraser and Harrison Ford, is inspired by the Crowley family journey.

11:15am - 12:15pm: Conference-Wide Panel: Overcoming Barriers in Translational Drug Development

Panelists:

• William Chin, MD, Executive Dean for Research, Bertarelli Professor of Translational Medical Science, Harvard Medical School
• Kris Joshi, PhD, GLobal Vice President, Healthcare Product Strategy, Health Sciences Global Business Unit, Oracle Corporation
• Bernat Olle, PhD, Principal, PureTech Ventures
• Jeffrey Voss, PhD, Senior Principal Research Scientist/Associate Director, AbbVie Pharmaceuticals

Moderator:

• Janet Wolfe, PhD, President and Chief Executive Officer, Wolfe Laboratories, Inc.

12:15pm - 1:00pm: Lunch Buffet

1:00pm - 1:15pm: Leading Edge Award Presentation

1:15pm - 2:00pm: Conference-Wide Panel: Research Resource Sharing: Challenges & Opportunities

Panelists:

• Reid Leonard, PhD, Managing Director, Merck Research Ventures Fund
• Elizabeth G. Nabel, MD, President, Brigham and Women's Health Care
• Paul Young, PhD, U.S. Head, External Innovation, EMD Serono, Inc.

Moderator:

• Andy Lee, Senior Vice President, Head Global Clinical Operations, Genzyme Corporation

2:15pm - 3:15pm: Concurrent Sessions II

Science Track: Oncology: Where are the Future Opportunities?

Panelists:

• Elan Ezickson, Executive Vice President and Chief Operating Officer, AVEO Oncology
• Sandra Glucksmann, PhD, Senior Vice President of Research and Development, Cerulean Pharma Inc.
• Clare Fisher, Business Development and Strategy, Blueprint Medicines

Moderator:

• Keting Chu, MD, PhD, Vice President, Research TAP, Leukemia & Lymphoma Society

Business Track: Healthcare Reimbursement Strategies

Panelists:

• Mohan Bala, PhD, Head, Oncology Pricing and Reimbursement, Sanofi
• David L. Van Brunt, PhD, Director, Health Economics and Outcomes Research, Biogen Idec
• Lisa Whittemore, Vice President, Network Performance Improvement, Blue Cross Blue Shield of Massachusetts

Moderator:

• Lujing Wang, MD, MPH, Managing Director, Commercial Center of Excellence, Campbell Alliance

3:15pm - 3:30pm: Coffee Break

3:30pm - 4:30pm: Concurrent Sessions III

Science Track: Neurodegenerative Diseases

Panelists:

• Samantha Budd, Vice President, Neuroscience iMed, AstraZeneca
• Bernard Ravina, MD, Medical Director, Translational Neurology, Biogen Idec
• Reisa Sperling, MD, Director, Center for Alzheimer Research and Treatment, Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School

Moderator:

• Stephen Knight, MD, President and Managing Partner, Fidelity Biosciences

Business Track: Rare Disease Therapies: Is the Current Payer Model Sustainable?

Panelists:

• Sam Rasty, PhD, Vice President, New Products, Shire HGT
• David Meeker, MD, President and CEO, Genzyme Corporation
• Claude Nicaise, MD, Senior Vice President of Strategic Product Development and Global Regulatory Affairs, Alexion Pharmaceuticals, Inc.

Moderator:

• Bruce Booth, DPhil, Partner, Atlas Ventures

4:30pm - 6:30pm: Reception

Friday, March 15

8:00am - 8:45am: Breakfast

8:45am – 9:45 am: Concurrent Session IV

Science Track: Antibody Drug Conjugates

Panelists:

• Godfrey Amphlett, PhD, Vice President, Process and Analytical Development, ImmunoGen, Inc.
• Timothy B. Lowinger, PhD, Chief Scientific Officer, Mersana Therapeutics, Inc.                  
• Lioudmila Tchistiakova, PhD, Senior Director, Global Biotherapeutic Technologies, Pfizer

Moderator:

• Janet Wolfe, PhD, President and Chief Executive Officer, Wolfe Laboratories, Inc.

Business Track: Antibiotics, Anti-infective, & Anti-Virals from a Business Perspective

Panelists:

• Steven C. Gilman, Ph.D., Executive Vice President, Research & Development and Chief Scientific Officer, Cubist Pharmaceuticals
• Mark C. Poznansky, MD, PhD, Director, Vaccine and Immunotheraphy Center, Massachusetts General Hospital
• Camille Nelson Kotton, MD, Clinical Director, Transplant and Immunocompromised Host Infectious Diseases, Infectious Diseases Division, Massachusetts General Hospital
• Y. Katherine Xu, PhD, Senior Research Analyst, Biotechnology at William Blair & Co.

Moderator:

• Mark Leuchtenberger, former CEO, Rib-X Pharmaceuticals

9:45am – 10:15am MassBio Board Elections and State of MassBio Address

• Robert K. Coughlin, President & CEO, MassBio
• Geoff Mackay, Chairman of the Board, MassBio; President & CEO, Organogenesis

10:15am – 10:45am Keynote II: Margaret Hamburg, MD, Commissioner, U.S. Food and Drug Administration

10:45am - 11:15am: Break

11:15am - 12:15pm Concurrent Session V

Science Track: RNA Therapeutics

Panelists:

• Chris Garabedian, President and CEO, Sarepta Therapeutics
• Art Krieg, MD, CEO, RaNA Therapeutics
• Rachel Meyers, PhD, Vice President, Research and RNAi Lead Development, Alnylam Pharmaceuticals                                              

 Moderator:

•  Mark Levin, Partner, Third Rock Ventures

Business Track: The Future of Biosimilars

Panelists:

• Gino Grampp, PhD, Regulatory Policy Director, Amgen
• Jim Roach, MD, SVP, Development and Chief Medical Officer, Momenta Pharmaceuticals, Inc.

Moderator:

• Kenneth I. Kaitin, PhD, Professor and Director, Tufts Center for the Study of Drug Development, Tufts University

12:15pm - 2:00pm: Awards Luncheon & Closing Remarks

• Henri Termeer Innovative Leadership Award Presentation
  
• Joshua Boger Innovative School of the Year Award Presentation